BSEAccretion Nutraveda LtdMediumPositive
Announced Fri, 15 May · 18:59 IST

Accretion Nutraveda Limited has informed the Exchange regarding Press Release dated 15th May, 2026, titled "Company Delivers Robust Performance in H2 FY26 : Revenue up 80.09% YOY and EBITDA ....

Regulatory Product ApprovalBusiness Updates View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹272.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.3-7.3-4.8-1.7
Up moveDown movePending
AI summary

Accretion Nutraveda Limited reported exceptional full-year FY26 results with net revenue of Rs. 33.60 crore, up 110% YoY from Rs. 16.00 crore in FY25. EBITDA grew 87.94% to Rs. 7.01 crore, while PAT surged 102.80% to Rs. 5.07 crore. H2 FY26 alone saw revenue of Rs. 19.54 crore, up 80.09% YoY, driven by strong demand for nutraceutical and ayurvedic products, expanded customer base, improved product mix, and higher CDMO services contribution. The company completed its IPO and BSE SME listing in February 2026, which is funding capacity expansion and automation initiatives. Management highlighted an export-led growth strategy with multiple products under registration and market approvals underway for international expansion.

Likely market impact

Strong double-digit growth across all metrics demonstrates solid execution and market expansion. The company is investing IPO proceeds into capacity enhancement, positioning it for continued growth in domestic and export markets.